|
|

Title: Abuse resistant tablets
United States Patent: 6,309,668
Inventors: Bastin; Richard James (Dagenham, GB); Lithgow;
Bruce Hamilton (Dagenham, GB)
Assignee: Aventis Pharma Limited (West Malling, GB)
Appl. No.: 676113
Filed: July 30, 1996
PCT Filed: January 24, 1995
PCT NO: PCT/GB95/00137
371 Date: July 30, 1996
102(e) Date: July 30, 1996
PCT PUB.NO.: WO95/20947
PCT PUB. Date: August 10, 1995
Foreign Application Priority Data: Feb 01, 1994[GB]
(9401894)
Abstract
This invention relates to an abuse resistant tablet containing two or
more layers having one or more drugs and one or more gelling agents and
its preparation. The drug(s) and gelling agent(s) are in separate layers
of the tablet. The multilayer tablet is particularly suitable for the
administration of drugs prone to abuse by unauthorized parenteral
administration such as analgesics, hypnotics, and anxiolytics.
Description of the Invention
This invention relates to abuse resistant tablets, to a
process for their preparation, and to their use in therapy. More
particularly, the present invention relates to abuse resistant tablets
comprising a plurality of layers.
It is known that many drugs intended for legitimate oral use have the
potential for abuse, whereby the drug may be extracted from a solid oral
dosage form to provide a solution which may be used for unauthorised,
unsupervised, illegal and/or dangerous parenteral administration. One way
of substantially reducing or even eliminating this potential for drug
abuse is to suppress or inhibit the extractibility of the drug from the
composition comprising the drug. In U.S. Pat. No. 4,070,494 this is
reported to have been achieved by incorporating in the composition an
aqueous gelable material present in sufficient quantity to form a gel when
combined with that volume of water otherwise necessary to dissolve all of
the medicinal agent. U.S. Pat. No. 4,070,494 describes enteral
compositions, including single and bilayer tablets, wherein the drug with
potential for abuse is mixed with the gelling agent and in the case of a
tablet is then pressed according to a conventional procedure. However,
such tablets comprising a gelling layer are liable to seriously retard the
release of the drug substance.
We have now found that release of the drug substance from a tablet
comprising a gelling agent is improved if the drug substance and the
gelling agent are present in separate layers of the tablet.
The present invention thus pertains to a tablet containing two or more
layers comprising one or more drugs and one or more gelling agents,
characterised in that the drug(s) and gelling agent(s) are contained in
separate layers of the tablet.
For the avoidance of doubt, it should be appreciated that the tablet may
comprise separate layers one stacked on top of the other in a sandwich
arrangement, or may comprise a core layer of gelling agent surrounded by
one or more layers comprising one or more drugs. The sandwich arrangement
is generally preferred.
Optionally the tablet has a coating which may or may not be a modified or
sustained release coating.
Suitable drugs which may be incorporated into the abuse resistant tablets
of the present invention include those which are particularly liable to
abuse, for example, analgesics, hypnotics and anxiolytics.
Specific examples of analgesic drugs which may be incorporated into
tablets of this invention include commercially available analgesic drugs,
such as codeine, pethidine, methadone and morphine.
Specific examples of hypnotic agents which may be incorporated into
tablets of this invention include benzodiazepines such as temazepam,
nitrazepam, flurazepam and loprazolam and non-benzodiazepines such as
chlormethiazole, zopiclone and zolpidem, and barbiturates such as
butobarbitone, phenobarbitone and amylobarbitone.
Specific examples of anxiolytic agents which may be incorporated into
tablets of this invention include diazepam, medazepam, oxazepam and
lorazepam.
The term "gelling agent" as used herein refers to a material
which forms a gel by the action of an aqueous medium, such as water or an
aqueous solution of an organic acid (e.g. aqueous citric or acetic acid),
a base (e.g. sodium bicarbonate or sodium tetraborate solution) or alcohol
(e.g. an aqueous lower alkanol such as aqueous ethanol or isopropanol).
Suitable gelling agents include, but are not limited to, modified
celluloses such as hydroxypropylmethylcellulose,
hydroxypropyl-ethylcellulose, methylcellulose, sodium
carboxymethylcellulose, and hydroxyethylcellulose, sodium alginate,
alginic acid, tragacanth, polyacrylic acid and xanthan, guar, locust bean
and karaya gums. Mixtures of two or more gelling agents may also be used.
Hereinafter, the layer or layers of the tablet containing the drug is
referred to as the "active layer" and the layer or layers
containing the gelling agent is referred to as the "gelling
layer".
The viscosity of the gelling agent in the gelling layer will generally be
within the range of about 1000 cp to about 100,000 cp. As used herein, the
term "cp" refers to centipoise which is a standard unit of
viscosity. One centipoise (cp) is equivalent to one millipascal second (mPa.s).
Preferably, the gelling agent will have a viscosity within the range of
about 4,000 cp to about 100,000 cp. More preferably, the gelling agent
will have a viscosity within the range of about 10,000 cp to about 100,000
cp.
It will be appreciated that the amount of gelling agent required in the
tablet depends upon features such as the nature of the active constituent,
the nature of the other excipients in the tablet, the weight of the tablet
and the viscosity grade of the gelling agent. The amount of gelling agent
present is preferably such that substantially no filterable material
remains when the tablet is triturated with the minimal amount of aqueous
medium needed to extract the drug. In general, the proportion of gelling
agent by weight in the gelling layer is from about 10 to about 70%,
preferably about 20 to about 60%, and most preferably about 30 to about
50%. The total amount of gelling layer in the tablet depends upon the
relative proportion of active and gelling layers but may typically be in
the range of about 20 to about 80% and preferably about 50 to about 80% by
weight.
The amount of drug in the active layer depends upon the therapeutic dose
required, as in conventional tablets. In general, the quantity of drug
which is incorporated into each tablet is often from about 0.5 mg to about
200 mg by weight, preferably from about 1 mg to about 100 mg, and most
preferably from about 1 mg to about 50 mg. In the case of zopiclone the
quantity of drug which is incorporated into each tablet is preferably
about 1 mg to about 10 mg.
The remainder of the active and gelling layers may consist of standard
tablet excipients known to those in the art, including but not limited to
diluents such as lactose, starches, cellulose and calcium hydrogen
phosphate, disintegrants such as starches, modified starches, celluloses
and modified celluloses, binders, glidants and lubricants.
The tablet may also contain materials known in the art intended for the
modification of release characteristics of the drug.
Preferably the active layer and the gelling layer are substantially
identical in colour and appearance, so that the join is not readily
visible to the potential abuser.
A coating, which may or may not be a modified or sustained release
coating, may advantageously be applied to a tablet according to the
present invention. A coated tablet is potentially advantageous when the
tablet layers are stacked in a sandwich construction in that the join
between the active layer and the gelling layer is further disguised.
In tablets according to the invention with more than two layers, one
surface of the active layer should be exposed to prevent retardation of
release of drug substance. Since one surface of the active layer is always
exposed and not in contact with the gelling layer in tablets according to
the present invention, release of drug can proceed relatively uninhibited
and at a rate substantially similar to that of conventional tablets which
do not possess a gelling layer.
In contrast, a combination of the active drug substance and gelling agent
in the same layer has the disadvantage that the gelling action is likely
to retard the release of the drug in a manner similar to some known
sustained release products which include water-swellable high molecular
weight polymers to retard drug release. Reduction of the gelling agent
concentration to a level which would not inhibit release of the drug
substance severely limits the abuse resistance potential of the tablet.
Drugs which may be particularly suitable for incorporation into the active
layer of a tablet according to the present invention include zopiclone,
temazepam, diazepam, zolpidem, codeine, methadone, pethidine, phenytoin
and phenobarbitone. A preferred drug for use according to the present
invention is zopiclone.
Gelling agents which may be particularly suitable for incorporation into
the gelling layer of a tablet according to the present invention include
modified celluloses and other high molecular weight polymers. Preferred
gelling agents include modified celluloses such as
hydroxypropylmethylcellulose, carboxymethylcellulose and methylcellulose
and xanthan gum, especially hydroxypropylmethylcellulose.
A preferred tablet of the present invention is a bilayer tablet in which
one layer comprises a drug and the other layer comprises a gelling agent.
However, the invention also covers further multilayered tablets such as
trilayered tablets.
It is to be understood that the present invention covers all appropriate
combinations of particular and preferred moieties comprised within a
tablet of the present invention as described herein.
According to a further feature of the invention there is provided a
process for the preparation of a tablet of the present invention, which
comprises forming the separate active and gelling layers, then combining
the layers in a suitable tabletting machine, optionally followed by the
application of a coating using a conventional coating procedure.
Tablets of the sandwich arrangement may conveniently be prepared by a
multistage compression process using a suitable tablet press, where the
first layer is compressed from a suitable powder and one or more
additional layers are compressed on top of the first or subsequent layers
to form a bilayer or multilayer tablet.
Tablets comprising a core of gelling layer surrounded by an active layer
may conveniently be prepared by first forming the core from a suitable
powder by compressing the powder using a suitable tablet press.
Thereafter, the core may be enclosed within the active layer or surrounded
by a cap of active layer using conventional means, such as using a tablet
press designed for compression coating.
Presses for the preparation of multilayer tablets according to the present
invention are either commercially available or may be provided by
modification of standard tabletting equipment.
Suitable coatings for tablets of the present invention include film
coatings to provide immediate release of the drug. Suitable film forming
materials include hydroxypropylmethylcellulose, hydroxypropylcellulose,
hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, polyethylene
glycols and acrylic polymers. Suitable film forming materials to provide
modified or sustained release include ethylcellulose, fats and waxes,
shellac, acrylic esters and phthalate or mellitate derivatives of
cellulose ethers and polyvinyl ethers. The flexibility and performance of
the film coat may be improved by the addition of plasticisers such as
polyhydric alcohols, acetate and phthalate esters, glycerides and oils.
According to a further aspect of the present invention there is provided a
method of treating a patient requiring an, analgesic, hypnotic or
anxiolytic drug, which method comprises administering to said patient said
drug comprised within a tablet according to the invention.
Claim 1 of 22 Claims
What is claimed is:
1. An abuse resistant tablet containing two or more layers comprising (1)
a drug and (2) a gelling agent, wherein the gelling agent has a viscosity
within the range of about 4,000 cp to about 100,000 cp, wherein the tablet
consists essentially of either (i) separate layers one stacked on top of
the other in a sandwich arrangement or (ii) a core layer comprising
gelling agent enclosed by one or more layers comprising one or more drugs,
wherein essentially all the drugs are contained in a separate layer or
layers from all gelling agents.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|